First Trust Advisors LP reduced its stake in shares of Steris Corp. (NYSE:STE) by 90.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,176 shares of the company’s stock after selling 66,281 shares during the period. First Trust Advisors LP’s holdings in Steris Corp. were worth $493,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. BKD Wealth Advisors LLC acquired a new position in shares of Steris Corp. during the second quarter valued at about $208,000. World Asset Management Inc boosted its position in shares of Steris Corp. by 0.3% in the second quarter. World Asset Management Inc now owns 4,197 shares of the company’s stock valued at $289,000 after buying an additional 13 shares during the period. Commonwealth Equity Services Inc boosted its position in shares of Steris Corp. by 1.3% in the second quarter. Commonwealth Equity Services Inc now owns 4,498 shares of the company’s stock valued at $309,000 after buying an additional 58 shares during the period. Mount Lucas Management LP acquired a new position in shares of Steris Corp. during the first quarter valued at about $313,000. Finally, Diversified Trust Co acquired a new position in shares of Steris Corp. during the second quarter valued at about $320,000. Hedge funds and other institutional investors own 91.58% of the company’s stock.
Steris Corp. (NYSE:STE) remained flat at $69.85 during midday trading on Wednesday. The company’s stock had a trading volume of 69,935 shares. Steris Corp. has a 12 month low of $61.38 and a 12 month high of $78.77. The company has a market cap of $6.02 billion, a P/E ratio of 40.12 and a beta of 1.14. The stock has a 50 day moving average price of $71.47 and a 200-day moving average price of $70.44.
Steris Corp. (NYSE:STE) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.02. The firm earned $638.40 million during the quarter, compared to analyst estimates of $639.04 million. Steris Corp. had a net margin of 5.52% and a return on equity of 10.72%. The business’s quarterly revenue was up 45.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 EPS. On average, analysts anticipate that Steris Corp. will post $3.90 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 27th. Stockholders of record on Tuesday, August 30th were issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.60%. This is a positive change from Steris Corp.’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend was Friday, August 26th. Steris Corp.’s payout ratio is presently 68.71%.
Separately, Zacks Investment Research upgraded shares of Steris Corp. from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd.
In other news, Director Richard Martin Steeves sold 204,778 shares of the business’s stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $71.19, for a total value of $14,578,145.82. Following the completion of the sale, the director now directly owns 165,434 shares in the company, valued at approximately $11,777,246.46. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Sudhir K. Pahwa sold 1,028 shares of the business’s stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $70.13, for a total transaction of $72,093.64. The disclosure for this sale can be found here. 2.52% of the stock is currently owned by insiders.
Steris Corp. Company Profile
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Corp. (NYSE:STE).
Receive News & Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related companies with MarketBeat.com's FREE daily email newsletter.